TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$145 Million

Sutro Biopharma

Follow-on Offering

Lead Left Bookrunner, December 2020

Sutro Biopharma

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company leveraging its cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders. Sutro aims to design therapeutics using the most potent modalities, including cytokine-based immuno-oncology therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies, directed against clinically validated targets where the current standard of care is suboptimal. Sutro’s lead, wholly-owned product candidate, STRO-002, is an ADC directed against folate receptor-alpha (FolRα) for patients with ovarian and endometrial cancers. Sutro is also developing STRO-001, an optimally designed ADC directed against the cancer target CD74 for multiple myeloma and non-Hodgkin’s lymphoma, or NHL.